Multilevel program to increase LDCT lung cancer screening and help African American smokers quit
Official title: Effectiveness of a Multilevel Integrated Intervention for LDCT Lung Cancer Screening and Smoking Cessation Among African Americans
Run by Louisiana State University Health Sciences Center in New Orleans · NCT07576595 · Data updated 2026-11-12
This program will try combining low-dose CT screening with culturally tailored smoking-cessation support to help African American smokers who are eligible for LDCT quit and get screened.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Louisiana State University Health Sciences Center in New Orleans Academic / other |
| Locations | 2 sites (New Orleans, Louisiana and 1 other locations) |
| Status | Recruiting |
| Started | April 17, 2025 |
| Main results expected | June 2029 |
| Study ends | June 2030 |
| Registry record updated | May 11, 2026 |
| Trial ID | NCT07576595 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are English-speaking African American current smokers with at least a 20 pack-year history who are eligible for or have received LDCT screening.
✕Probably not a fit
People who are not current smokers, have less than a 20 pack-year history, or are not eligible for LDCT screening are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The intervention (MILS) integrates low-dose CT (LDCT) lung cancer screening with a multilevel, culturally tailored smoking cessation program using community-engaged methods and NIH DEIA-aligned strategies. The approach targets individual, interpersonal, and health-system determinants to increase screening uptake and promote sustained quitting among African American smokers with 20+ pack-years. Outcomes include LDCT uptake, smoking cessation rates, and measures of reach and acceptability within the targeted communities. The program is implemented at LSUHSC School of Public Health and University Medical Center in New Orleans and uses coordinated clinical and community resources.
Why it matters
Potential benefit: If successful, the intervention could increase LDCT screening and quit rates among African American smokers and help reduce lung cancer disparities.
How similar studies have gone: Previous work shows LDCT can serve as a teachable moment that increases quit attempts, but comprehensive, culturally tailored multilevel programs for African Americans are limited, so this integrated approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * African American * 20+ pack years of smoking * eligible for or received LDCT screening * current smoker * English speaking Exclusion Criteria: * N/A
Where it's running
-
LSUHSC School of Public Health
New Orleans, Louisiana, United States Recruiting -
University Medical Center
New Orleans, Louisiana, United States Recruiting
Study contacts
- Principal investigator: Tung Sung Tseng, DrPH, MS — LSUHSC New Orleans
- Study coordinator: Jessica Kassner, MS, MPH
- Email: jkassn@lsuhsc.edu
- Phone: 504-568-5724
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CONNECT Multilingual: Helping Spanish and Cantonese Speakers Quit Smoking During Lung Cancer Screening
This trial tests a multilingual version of the CONNECT program to help current adult smokers who speak Spanish or Cantonese quit smoking while undergoing lung cancer screening.
-
Education program for quitting smoking
This study is testing an education program to help people with mental health disorders who smoke to quit by providing support from nurses.
-
Quitting Matters: a smoking quit program for people living with HIV
This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.
-
tDCS plus varenicline to help people quit smoking
This will test if adding noninvasive tDCS brain stimulation to varenicline helps adults who smoke at least 8 cigarettes a day quit and stay smoke-free.
-
Effects of Cytisinicline on Smoking Cues in Daily Smokers
This study tests if a medication called cytisinicline can help daily smokers reduce their cravings and reactions to cigarette-related triggers.
-
Counseling methods for quitting smoking
This study is testing whether video counseling can help older smokers quit smoking just as well as traditional in-person counseling.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.